Edward J Gane1,2, Régine Rouzier3, Tarek Hassanein4, Catherine A Stedman5, Wlodzimierz Mazur6, Viera Kupcova7, Sophie Le Pogam8, Simon Eng9, Athina Voulgari10, Peter N Morcos8, Barbara J Brennan8, Astrid Scalori10, James Thommes9. 1. Auckland Clinical Studies, Grafton, New Zealand. edgane@adhb.govt.nz. 2. Auckland City Hospital, Auckland, 1442, New Zealand. edgane@adhb.govt.nz. 3. Centre Cap, Centre Médical Odysséum, Montpellier, France. 4. Southern California Liver Centers, Coronado, CA, USA. 5. Christchurch Clinical Studies and University of Otago, Christchurch, New Zealand. 6. Department of Infectious Diseases, Medical University of Silesia, Katowice, Poland. 7. Medical Faculty of Comenius University, Dérer's Hospital, Bratislava, Slovakia. 8. Hoffmann-La Roche Inc, Nutley, NJ, USA. 9. Genentech, South San Francisco, CA, USA. 10. Roche Products Ltd, Welwyn, UK.
Abstract
BACKGROUND AND AIM: Effective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and cirrhosis. METHODS: An international open-label trial was conducted in CHC patients with genotype (G)1/4 infection, compensated cirrhosis, HCV RNA ≥ 50,000 IU/mL and body mass index 18-35 kg/m(2). Treatment-naive patients (Cohort 1) received a triple therapy regimen [danoprevir/r 100/100 mg twice daily (bid), ribavirin 1000/1200 mg/day and peginterferon alfa-2a 180 µg/week] for 24 weeks. Prior null responders (Cohort 2) received a quadruple therapy regimen (danoprevir/r 100/100 mg bid, mericitabine 1000 mg bid and peginterferon alfa-2a/ribavirin). The primary efficacy outcome was sustained virological response (HCV RNA < limit of quantification, target not detected) at end of the 24-week follow-up period (SVR24). RESULTS: In Cohort 1 (n = 23), 73.9 and 65.2 % of patients had a virological response at Weeks 4 and 24, respectively; 39.1 % achieved SVR24 (G1a = 1/13; G1b = 8/9; G4 = 0/1). In Cohort 2 (n = 20), 100 % achieved virological response at Weeks 4 and 24; 65 % achieved SVR24 (G1a = 4/8; G1b = 7/10; G4 = 2/2). Treatment failure was more common in G1a than G1b-infected patients and less common in patients receiving quadruple therapy. Treatment failure was associated with emergence of resistance to danoprevir, but not mericitabine. The safety profile was typical of that associated with peginterferon alfa-2a/ribavirin. No deaths/episodes of hepatic decompensation occurred. CONCLUSIONS: Treatment with danoprevir/r-based regimens for 24 weeks is safe and well tolerated in CHC patients with compensated cirrhosis. A quadruple therapy regimen (danoprevir/r, mericitabine, peginterferon alfa/ribavirin) produced high SVR24 rates in prior null responders, particularly among G1b patients.
BACKGROUND AND AIM: Effective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and cirrhosis. METHODS: An international open-label trial was conducted in CHC patients with genotype (G)1/4 infection, compensated cirrhosis, HCV RNA ≥ 50,000 IU/mL and body mass index 18-35 kg/m(2). Treatment-naive patients (Cohort 1) received a triple therapy regimen [danoprevir/r 100/100 mg twice daily (bid), ribavirin 1000/1200 mg/day and peginterferon alfa-2a 180 µg/week] for 24 weeks. Prior null responders (Cohort 2) received a quadruple therapy regimen (danoprevir/r 100/100 mg bid, mericitabine 1000 mg bid and peginterferon alfa-2a/ribavirin). The primary efficacy outcome was sustained virological response (HCV RNA < limit of quantification, target not detected) at end of the 24-week follow-up period (SVR24). RESULTS: In Cohort 1 (n = 23), 73.9 and 65.2 % of patients had a virological response at Weeks 4 and 24, respectively; 39.1 % achieved SVR24 (G1a = 1/13; G1b = 8/9; G4 = 0/1). In Cohort 2 (n = 20), 100 % achieved virological response at Weeks 4 and 24; 65 % achieved SVR24 (G1a = 4/8; G1b = 7/10; G4 = 2/2). Treatment failure was more common in G1a than G1b-infected patients and less common in patients receiving quadruple therapy. Treatment failure was associated with emergence of resistance to danoprevir, but not mericitabine. The safety profile was typical of that associated with peginterferon alfa-2a/ribavirin. No deaths/episodes of hepatic decompensation occurred. CONCLUSIONS: Treatment with danoprevir/r-based regimens for 24 weeks is safe and well tolerated in CHC patients with compensated cirrhosis. A quadruple therapy regimen (danoprevir/r, mericitabine, peginterferon alfa/ribavirin) produced high SVR24 rates in prior null responders, particularly among G1b patients.
Authors: Ira M Jacobson; John G McHutchison; Geoffrey Dusheiko; Adrian M Di Bisceglie; K Rajender Reddy; Natalie H Bzowej; Patrick Marcellin; Andrew J Muir; Peter Ferenci; Robert Flisiak; Jacob George; Mario Rizzetto; Daniel Shouval; Ricard Sola; Ruben A Terg; Eric M Yoshida; Nathalie Adda; Leif Bengtsson; Abdul J Sankoh; Tara L Kieffer; Shelley George; Robert S Kauffman; Stefan Zeuzem Journal: N Engl J Med Date: 2011-06-23 Impact factor: 91.245
Authors: Edward J Gane; Stuart K Roberts; Catherine A M Stedman; Peter W Angus; Brett Ritchie; Rob Elston; David Ipe; Peter N Morcos; Linda Baher; Isabel Najera; Tom Chu; Uri Lopatin; M Michelle Berrey; William Bradford; Mark Laughlin; Nancy S Shulman; Patrick F Smith Journal: Lancet Date: 2010-10-14 Impact factor: 79.321
Authors: A J Muir; L Gong; S G Johnson; M T M Lee; M S Williams; T E Klein; K E Caudle; D R Nelson Journal: Clin Pharmacol Ther Date: 2013-10-04 Impact factor: 6.875
Authors: Paul J Pockros; Donald Jensen; Naoky Tsai; Ryan Taylor; Alnoor Ramji; Curtis Cooper; Rolland Dickson; Alan Tice; Rohit Kulkarni; John M Vierling; Marie Lou Munson; Ya-Chi Chen; Isabel Najera; James Thommes Journal: Hepatology Date: 2013-06-24 Impact factor: 17.425
Authors: Patrick Marcellin; Curtis Cooper; Luis Balart; Dominique Larrey; Terry Box; Eric Yoshida; Eric Lawitz; Peter Buggisch; Peter Ferenci; Martin Weltman; Emily Labriola-Tompkins; Sophie Le Pogam; Isabel Nájera; Denise Thomas; Gregory Hooper; Nancy S Shulman; Ying Zhang; Mercidita T Navarro; Chin Yin Lim; Michael Brunda; Norah A Terrault; Ellen S Yetzer Journal: Gastroenterology Date: 2013-06-26 Impact factor: 22.682
Authors: Savino Bruno; John M Vierling; Rafael Esteban; Lisa M Nyberg; Hugo Tanno; Zachary Goodman; Fred Poordad; Bruce Bacon; Keith Gottesdiener; Lisa D Pedicone; Janice K Albrecht; Clifford A Brass; Seth Thompson; Margaret H Burroughs Journal: J Hepatol Date: 2012-11-23 Impact factor: 25.083
Authors: Sophie Le Pogam; Amritha Seshaadri; Aren Ewing; Hyunsoon Kang; Alan Kosaka; Jun-Mei Yan; Michelle Berrey; Bill Symonds; Abel De La Rosa; Nick Cammack; Isabel Nájera Journal: J Infect Dis Date: 2010-10-13 Impact factor: 5.226
Authors: Eric Lawitz; Fred F Poordad; Phillip S Pang; Robert H Hyland; Xiao Ding; Hongmei Mo; William T Symonds; John G McHutchison; Fernando E Membreno Journal: Lancet Date: 2013-11-05 Impact factor: 79.321